Izotropic (FRA:1R3) EBIT: €-1.42 Mil (TTM As of Jan. 2026)


FRA:1R3 Izotropic Corp FRA:1R3
28 GF Score
Price €0.14
! 2 Warning Signs
View Full Analysis

What is Izotropic EBIT?

Izotropic FRA:1R3 28 EBIT is €-1.42 Mil as of Jan. 2026. GuruFocus rates FRA:1R3 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Izotropic's earnings before interest and taxes (EBIT) for the three months ended in Jan. 2026 was €-0.12 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jan. 2026 was €-1.42 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Izotropic's annualized ROC % for the quarter that ended in Jan. 2026 was -46.77%. Izotropic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -1,294.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Izotropic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -11.45%.

Izotropic  (FRA:1R3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Izotropic's annualized ROC % for the quarter that ended in Jan. 2026 is calculated as:

ROC % (Q: Jan. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2025 ) + Invested Capital (Q: Jan. 2026 ))/ count )
=-0.888 * ( 1 - 0% )/( (1.827 + 1.97)/ 2 )
=-0.888/1.8985
=-46.77 %

where

Invested Capital(Q: Oct. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.275 - 1.828 - ( 0.141 - max(0, 3.652 - 0.272+0.141))
=1.827

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.423 - 1.787 - ( 0.225 - max(0, 3.684 - 0.35+0.225))
=1.97

Note: The Operating Income data used here is four times the quarterly (Jan. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Izotropic's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2025  Q: Jan. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.492/( ( (0.002 + max(-1.704, 0)) + (0.074 + max(-1.665, 0)) )/ 2 )
=-0.492/( ( 0.002 + 0.074 )/ 2 )
=-0.492/0.038
=-1,294.74 %

where Working Capital is:

Working Capital(Q: Oct. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.125) - (1.828 + 0 + 0.0010000000000003)
=-1.704

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.122) - (1.787 + 0 + 0)
=-1.665

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Izotropic's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jan. 2026 )
=-1.421/12.407
=-11.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Izotropic EBIT Related Terms

Izotropic EBIT Historical Data

* Premium members only.

The historical data trend for Izotropic's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Izotropic EBIT Chart

Izotropic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
EBIT
Get a 7-Day Free Trial Premium Member Only -3.33 -4.87 -3.63 -0.89 -1.82

Izotropic Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.60 -0.23 -0.47 -0.12

FRA:1R3 vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Izotropic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Izotropic EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Izotropic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Izotropic's EV-to-EBIT falls into.


FRA:1R3
28GF Score
Izotropic Corp FRA:1R3
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Izotropic EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-1.42 Mil mean?
Izotropic (FRA:1R3) has a EBIT of €-1.42 Mil as of Jan. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Izotropic.
Is Izotropic's EBIT too high?
Izotropic's current EBIT is €-1.42 Mil. Overall, Izotropic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Izotropic's EBIT compare to TMO and DHR?
Izotropic's EBIT of €-1.42 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Izotropic. Izotropic's current EBIT is €-1.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Izotropic stock overvalued right now?
Izotropic (FRA:1R3) has a current EBIT of €-1.42 Mil. The current EBIT is €-1.42 Mil. Izotropic's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Izotropic (FRA:1R3), the current EBIT is €-1.42 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Izotropic Business Description

Address 800 - 15355 24th Avenue, Suite 424, Surrey, BC, CAN, V4A 2H9
Izotropic Corp is a research and development company specializing in cancer research and early detection for breast cancer. It is engaged in advancing breast cancer imaging through the commercialization of medical imaging technologies. The company's current focus is on the commercialization of its first medical imaging device, IzoView, a dedicated Breast CT Imaging System, developed to provide high resolution, true 3D volumetric visualization of the breast without compression for breast cancer detection and diagnosis.
28GF Score

Get the complete analysis for FRA:1R3

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.14
Price